Multi drug resistant tuberculosis: a challenge in the management of tuberculosis by Amukoye, E
African Journal of Health Sciences, Volume 15, Number 1, January- March 2008 6





Center for Respiratory Diseases Research; Kenya Medical Research Institute (KEMRI), P. O. Box 54840-





Multi drug resistant tuberculosis (MDR-TB) will not usually respond to short 
course chemotherapy. Unless the individual infected with this bug is treated 
appropriately, they can continue spreading resistant strains in the community and 
further fuel the tuberculosis epidemic. Diagnosis requires drug sensitivity testing 
and the capability to do this is not widely available. Multi drug resistant 
tuberculosis has been reported all over Africa but the prevalence is still low. The 
treatment is not only expensive but also quite prolonged and compliance cannot be 
overemphasized.  The recent outbreaks of extensive drug resistant TB further 
complicate the management and control of the disease.  This is a perspective on 
challenges of managing MDR TB and its effect on the control program the 
information presented is gathered from published data. 
 




Tuberculosis (TB) is one of the fastest growing 
epidemics.  Worldwide over 1 billion people are 
infected with dormant TB.  Nine to eleven 
million people have active TB predominately in 
Asia, Africa, and Latin America, and almost 3 
million people die of TB annually, including 
half a million children.  WHO estimates that 4.5 
million people are co-infected with the human 
immunodeficiency virus (HIV) and TB. TB 
flourishes where there is poverty, malnutrition, 
overcrowding, and deficient health care [1]. In 
Kenya the notification rate of all forms of TB 
over the past 5 years has been increasing by an 
average of 14%. Reported cases of Tuberculosis 
have risen from 10,000 in the 1980s to over 
100,000 in 2004 [2]. The increase has been 
driven mainly by the high prevalence of HIV in 
the population. It is estimated that up to 60% of 
TB patients are co-infected with HIV in Kenya 
[2]. MDR TB, which has been demonstrated to 
occur in indigenous Kenyans, could complicate 








Multi-drug resistant (MDR) Tuberculosis refers 
to resistance in vitro to at least Isoniazide (INH) 
and rifampicin (RIF). Resistance to at least two 
drugs other than the combination of INH and 
RIF is known as polyresistant tuberculosis and 
monoresistance is the resistance due to only one 
anti-tuberculosis medication [4].  This definition 
is based on the fact that INH plus RIF is the 
most important combination and resistant to 
them will lead to failure of short course 
chemotherapy even though resistant to other 
drugs could also lead to failure. MDR TB may 
be due to acquired resistance, that is strain of M. 
tuberculosis that was initially sensitive to DOTS 
drugs, but becomes resistant to drugs within an 
individual in the setting of low drug levels, 
intermittent therapy or effective monotherapy.  
Primary resistance is infection with a strain in 
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M. tuberculosis that is already resistant to 
important first-line drugs [4]. 
           Cases of MDR TB have been documented 
throughout the world including in the United 
States, South America, Central America, Africa, 
Mexico, Russia and the former Soviet Union, 
Western Europe, Eastern Europe, the Caribbean, 
Asia, New Zealand and Austria.  The problem 
has been growing over the past several years and 
mathematical modeling suggests that unless a 
concerted effort is made to stop MDR TB, it will 
become a major public health problem on 
several continents’ [3-14]. 
 
Causes 
Effective therapy for disease due to M. 
tuberculosis was discovered in l943, when 
streptomycin (SM) was identified. It was noticed 
that patients with TB who initially improved on 
SM often failed therapy; they no longer then 
responded to the drug, even at higher doses.  
Although a single potent drug could often 
eradicate the majority of tubercle bacilli, natural 
mutants resistant to that drug survived to 
become the dominant strain [15].  This mutant 
was then transmitted to other members of the 
community.  INH and paramino salicylic acid 
(PAS) were developed shortly after SM, but 
when used alone, they would also develop 
acquired resistance [16,17].  It was then 
recognized that combinations of antituberculous 
drugs could prevent the development of drug 
resistance and thus, treatment regimens 
including more than one antituberculous drug 
became the standard of care. 
        It is worth reiterating that MDR TB, a 
relatively new threat to health, is an entirely 
man-made phenomenon; antituberculous drug 
resistance is the result, ultimately, of poor 
therapeutic practices [18].  If TB-control efforts 
had been well organized decades ago, it is likely 
that the dimensions of this problem would be 
significantly smaller.  Thus, the introduction of 
systematic and effective control of drug-
sensitive TB, through DOTS, is our best weapon 
against the generation of drug resistance [19]. 
          Directly Observed Therapy, Short Course 
(DOTS) refers to a specific type of tuberculosis-
control program, requiring the following 
elements: 1) government commitment to a 
National Tuberculosis Program; 2) passive case-
finding in general health services by sputum 
smear microscopy examination of samples from 
suspected TB cases; 3) standardized short-course 
chemotherapy administered to at least all smear-
positive TB cases under specified case-
management conditions with therapy being 
directly observed; 4) regular uninterrupted 
supply of all essential antituberculous drugs; and 
5) a monitoring system for program supervision 
and evaluation. A strategy to manage MDR TB 
that takes advantage of the many strengths of the 
DOTS strategy is known as “DOTS-Plus” 
[19,20]. 
        Failure of DOTS to adequately treat drug-
resistant TB (whether polyresistant or MDR TB) 
lead to generation of further resistance and 
ultimately the circulation of highly resistant 
strains of M. tuberculosis.  The result of the 
generation of high-grade drug resistance by 
inadequate therapy is not only grave for the 
patient, but for the community at large, as drug-
resistant strains are spread by the same airborne, 
person-to-person mechanism as a susceptible 
strains of TB Drugs.  DOTS is ineffective for 
curing either form of MDR TB and for 
preventing further spread of drug-resistant 
strains in the community.  It is worth to note that 
not all re-treatment cases of tuberculosis have 
MDR. In Malawi of 164 culture positive, 81% 
(122) were fully sensitive and only 4% (6) had 
MDR [21] 
Factors that favor the development and spread of 
MDR-TB are incomplete or inadequate therapy 
that can select for drug-resistant mutants of M 
tuberculosis.  Prolonged infectiousness of 
patients due to delayed diagnosis of MDR TB 
and to the absence of effective therapy also 
allows ongoing transmission of drug-resistant 
strains to susceptible contacts. Patients with 
cavitary lesion have a tendency to have a more 
chronic illness and higher chance of having 
MDR and should be isolated especially from 
immuno-compromised HIV patients [7]. 
         Patients infected with primary drug-
resistant TB treated with short-course 
chemotherapy are less likely to be cured. 
Patients sick with drug-resistant TB exposed to 
short-course chemotherapy can further acquire 
resistance through inadvertent monotherapy 
(“the amplifier effect”) [22] 
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Kenyan situation 
Since the introduction of short course 
chemotherapy in Kenya in 1993, the treatment 
success rate has been about 80%, the death rate 
reduced from 1% to 0.4%. In 2003 7% of all TB 
treatment were on re-treatment regime [2]. 
Though there is usually a higher drug resistance 
in the re-treatment population, it may not be 
evidence of MDR and outcome of re-treatment 
may be good, as shown in a study done in 
Malawi [21].  A well run control program such is 
available in Kenya is important in reducing 
secondary (acquired) drug resistance. In 1995 
MDR was not reported in general population but 
was isolated among the refugees. [3] This is no 
longer so as patient seeking culture services at 
the Kenya Medical Research Institute (KEMRI), 
11.4% of the 983 specimen tested positive for 
MDR tuberculosis [23,24].  This was the first 
time MDR was documented in indigenous 
Kenyans, even though there have been sporadic 
reports of MDR from public and private sector. 
KEMRI has undertaken a survey of drug 
resistant Tuberculosis and the results will soon 
be published. In Ethiopia, our neighbour, Multi-
drug-resistance (MDR) TB was reported to be 
about 1.2% of new cases and 12% of re-
treatment cases [25]. 
 
Situation in children 
It is difficult to diagnose MDR tuberculosis in 
children and this results in delay in treatment. In 
South Africa the median age of diagnosing 
tuberculosis was 4.5 years at first TB diagnosis 
and 6.2 years on MDR culture confirmation. 
Delay in starting appropriate MDR treatment 
after TB diagnosis was a median of 2 days if 
MDR TB source cases were taken into account, 
but 246 days if the drug susceptibility pattern of 
the source case was not considered, and 283 
days if there was no known tuberculosis source 
case. Seventeen children had smear positive 
tuberculosis, of which 13 had cavitatory 
pulmonary disease. Eight children had central 
nervous system TB. Thirty-six children were 
treated for MDR tuberculosis, of whom four 
died. Obtaining a detailed contact history and 
their culture and sensitivity result is essential in 
reducing the delay in starting treatment. Delay 
of starting appropriate MDR anti-tuberculosis 
treatment has potentially serious consequences 
[26]. 
 
DOTs-plus strategy  
Evidence, and consequent estimates, suggested 
that the MDR situation in developing Countries, 
especially in sub-Saharan Africa, is deteriorating 
rapidly [27]. Similarly, major increases in 
tuberculosis have been observed in the former 
USSR. It was estimated that some 7-8 million 
new cases and 2-3 million deaths were occurring 
annually in the world. The global targets of 
reaching 85% cure rates and 70% case detection 
among infectious cases were established by the 
World Health Assembly in 1991. The WHO 
declaration of TB as a global emergency in 1993 
and the launch of the five-element DOTS 
strategy in 1994-1995 resulted in countries 
adopting DOTS in encouraging numbers. In 
2000, 148 countries including all 22 highest 
burden countries (HBC) responsible for 80% of 
cases worldwide, had adopted the new DOTS 
strategy [27] 
 
WHO position statement on MDR TB is 
• To achieve TB control worldwide and to 
prevent the emergence of anti-
tuberculous drug resistance, the WHO 
considers implementation of sound TB-
control based on the DOTS strategy as a 
top priority. 
• Recognizing that MDR TB is a 
considerable threat to the effectiveness 
of DOTS in some areas of the world, 
WHO strongly supports pilot projects to 
assess the feasibility of DOTS-Plus 
interventions in a variety of settings, 
provided DOTS is in place. 
• Based on the results of these pilot 
projects, WHO and its partners in the 
newly established Working Group on 
DOTS-Plus for MDR TB will formulate 
international policy recommendations 
on MDR TB management. [19] 
 
Effects of HIV on MDR TB 
History of previous TB treatment, and not HIV 
infection, was the principal factor associated 
with TB, which is resistant to at least one 
primary anti-TB Drug. HIV co-infection can 
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shorten the period from TB infection to disease 
leading to lengthier periods of infectiousness. In 
a population-based representative data on new 
and previously treated patients with TB 
collected within an international drug resistance 
surveillance network, Espinal et al concluded 
that prior but ineffective treatment is a strong 
predictor of drug resistance, and that HIV is not 
an independent risk factor for MDR-TB [28]. 
         The association between length of 
treatment and drug resistance may reflect longer 
treatment as a result of treatment failure in 
patients with drug resistance; it may also reflect 
irregular prior treatment for TB, leading to drug 
resistance.  However, as the HIV epidemic 
progresses in a milieu of high TB prevalence, 
the link with drug-resistant TB warrants constant 
monitoring and investigation [28].  
 
Treatment of MDR TB 
Management of MDR-TB relies on prompt 
recognition. Traditional culture of 
Mycobacterium tuberculosis isolates on solid 
media is slow, a commercialized molecular 
genetic test for a limited number of target loci 
might be a good alternative for a drug 
resistance-screening test in the context of an 
MDR “DOTS-plus” strategy [29]. 
           DOT-plus strategy is more crucial in the 
treatment of MDR TB because of the extended 
duration and the potential for greater side effect. 
Emerging data suggest that in younger patients 
with little co-morbidity, the occurrence of 
serious adverse effect is rare and does not 
compromise treatment outcome. Trained 
individuals with experience in second line drugs 
are preferred to supervise therapy, but 
administration of medication in health centers 
could promote transmission of nosocomial MDR 
TB. A number of studies have demonstrated the 
effectiveness of community health workers in 
responding to serious challenges to health. The 
value of directly observed therapy in the 
treatment of MDR TB can not be 
underestimated, this could include mouth check 
after swallowing drugs, serum check where this 
is available and/or examining for side effect 
such as bronzing of the skin with clofazimine to 
ensure adherence. 
          The foundation of treatment consists four 
to five drugs to which the infecting bug is 
(likely) susceptible. The regime should include a 
parenteral drug, a first line drug to which the 
infective strain is likely susceptible and a 
fluoroquinolone whenever possible. Choose 
bactericidal (more efficacious) to which the 
patient has no allergy. Tuberculosis is 
sometimes partially resistant to Isoniazide, in 
such situations it can be used at a higher dose in 
conjunction with pyridoxine. Isoniazide can’t be 
used in higher doses in conjunction with 
pyridoxine in situations where TB is fully 
resistant to it. Adjuvant treatments that can be 
used include the use of cortcosteroids in patients 
with severe respiratory distress, central nervous 
system involvement or laryngeal TB to try and 
prevent permanent sequelae of chronic 
inflammation. Surgery has been recommended 
with good results in patients with unilateral or 
focal disease that has no clinical response after 3 
to 6 months of specific therapy. Other 
indications of surgery are high-grade resistance 
with extensive parenchymal damage, recurrence 
of positive smear or culture during or after 
treatment. [30]. 
 
Adverse drug reactions 
The adverse drug reactions depend on drugs 
used. The following are some of the documented 
adverse reaction: Nervous system- includes 
headache, weakness, fatigue somnolence and 
insomnia. More serious reaction includes 
seizure, peripheral neuropathy, ototoxicity, optic 
neuritis and psychiatric reaction. Gastrointestinal 
side effects -are nausea, vomiting, diarrhea, 
bloating, abdominal cramps and gastritis. Rarely 
gastric ulcer or hepatitis may occur. 
        Endocrine effect such as worsening of 
glycemic control in diabetics, changes in 
menstrual period and hypothyroidism may 
occur. 
       Dermatological reactions such a skin color 
changes, photosensitive, and dry skin are 
frequently observed, while anaphylaxis and 
Stevens-Johnson syndrome are rare but 
potentially lethal. Renal and electrolyte 
disturbances include acute renal insufficiency, 
nephrolithiasis, proteinuria hypokalemia and 
hypomagnesemia. 
      Other minor adverse effects include 
arthralgias, myalgias, cramps and candidal 
vaginitis. Dehydration and/or weight loss, 
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associated with gastrointestinal symptoms, may 
occur in the early months of treatment. [31-38]. 
 
Duration of treatment 
Treatment of MDR TB is long, it is 
recommended that parenteral medication should 
continue for six months and oral medicine 
should continue until there is 18 to 24 months of 
culture negative sputum (specimen). Clinical 
response, radiological response and degree of 
resistance also determine the duration of 
treatment. After terminating treatment routine 
follow up and specimen collected for culture 
every 6 months for 24 months [39]. The 
prognosis of patients treated for MDR TB has 
been improving as effective drugs become 
available and as experience is gained in treating 
this condition. In a study done in South Africa 
out of 443 patients infected with MDR TB after 
5 years 44% had died, 15% had severe chronic 
respiratory disease, and only 33% we cured. The 
situation has improved with almost an 80% cure 
in some setting where DOTs- plus is practiced 
[40]. 
 
Extensive drug resistance (XDR) 
Physician working in Kwazula Natal, South 
Africa in 2005 noticed rapid deaths among 
patients with co-infection of TB and HIV [41].  
Gadhi et al compiled 1539 patients with 
tuberculosis from this area.  MDR was detected 
in 221 of these patients of whom 53 had XDR.  
All of those tested for HIV (44) were HIV 
positive.  52 of 53 patients died with median 
survival of 16 days from the time of diagnosis.  
85% of the isolates had similar strain.  55% of 
these patients had not previously been treated 
[42].  XDR tuberculosis is defined as MDR 
(Resistant Rifampicin and Isoniazid) as well as 
resistant to at least two of the 6 primary classes 
of second line drugs, one being a 
fluoroquonolone and the other an injectable drug 
[43]. Centers for Disease Control (CDC) and 
WHO in 2006 documented XDR in at least 17 
countries.  The data showed 10% of MDR were 
XDR.  Data from USA, Latin and Kofa showed 
that the XDR rates range from 4% to 19% 
among MDR isolates [41].  
            Since a percentage of MDR is XDR it 
means that XDR must be existing in Kenya 
though the number may be small as MDR is not 
yet a major problem in this country.  The cause 
of MDR and XDR is due to inappropriate use of  
first line and second line drugs and the failure to 
diagnosis patients leads to increased spread of 
the strains diseases.  Therefore it is necessary to 
strengthen the laboratory capacity and improve 
adherence to taking tuberculosis drugs or 
otherwise face a situation in which the spread of 
TB will be driven by both HIV scourge and 
MDR/XDR. Research into new drug sneed to be 




The prevalence of MDR Tuberculosis is still low 
in Africa compared to Eastern Europe, but it is 
growing and should be addressed in time. Even 
though the price of treatment was brought down 
in countries such as Peru. The cost of treating 
MDR TB in Kenya is estimated to be 1.3 million 
Kenya Shilling (personal communication by 
NLTP manager) which is out of the reach of 
most of its citizen. While HIV is fueling the TB 
epidemic in sub- Sahara, MDR does the same in 
Eastern Europe. We are facing a situation in 
which we will have MDR, HIV mixed in a 
milieu of poverty, a situation we dare not 
imagine.  
        Kenya should endeavor to reduce the 
emergence and spread of MDR-TB by 
emphasizing on strict adherence to DOTs 
strategy. TB drugs should be administered in 
DOTs registered centers. Any patient with 
evidence of long standing disease such as 
demonstration of cavities on chest X-ray, should 
be isolated until drug sensitivity result is known, 
as MDR-TB is common in long standing 
disease. All patients with MDR-TB should be 
treated promptly therefore the effort the National 
Leprosy and Tuberculosis Program to introduce 
DOTS-plus is highly supported. The 
introduction of DOTS-plus could also 
remarkably reduce the cost of treating MDR-TB. 
         The management of XDR will remain a 
challenge as there is a no effective treatment and 
isolation for indefinite period could raise human 
right issues.  Health workers working with 
patients infected with MDR/XDR or even 
suspect TB should have HIV tests regularly.  
Those found positive should opt to work in less 
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risky environments. I conclude by stating that 
MDR/XDR tuberculosis is a growing threat in 
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